Parameningeal Rhabdomyosarcoma: Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study.
Loading...
Embargo End Date
ICR Authors
Authors
Schoot, RA
Taselaar, P
Scarzello, G
Kolb, F
Coppadoro, B
Horst, ST
Mandeville, H
Ferrari, A
Hladun, R
Helfre, S
Ferman, S
Kelsey, A
Hol, MLF
Devalck, C
Ben-Arush, M
Orbach, D
Chisholm, J
Jenney, M
Minard-Colin, V
Bisogno, G
Merks, JHM
Taselaar, P
Scarzello, G
Kolb, F
Coppadoro, B
Horst, ST
Mandeville, H
Ferrari, A
Hladun, R
Helfre, S
Ferman, S
Kelsey, A
Hol, MLF
Devalck, C
Ben-Arush, M
Orbach, D
Chisholm, J
Jenney, M
Minard-Colin, V
Bisogno, G
Merks, JHM
Document Type
Journal Article
Date
2024-11-15
Date Accepted
2024-10-28
Abstract
BACKGROUND: Parameningeal (PM) site is an unfavorable characteristic in rhabdomyosarcoma (RMS). We described the treatment and outcome for patients with PM RMS and investigated the prognostic value of risk factors. We scored PM site by originating site and by highest risk extension. METHODS: Patients with PM RMS were treated within the European pediatric Soft tissue sarcoma Study Group (EpSSG) RMS 2005 study with risk-adapted, multi-modal treatment. RESULTS: Three-hundred-eighty-one patients with PM RMS were included. Radiotherapy was administered in 359 patients (77 with surgery). After a median follow-up of 75 months, 5-year event-free survival was 60% (95% confidence interval (CI) 55%-65%), 5-year overall survival was 65% (95% CI 60%-70%). CONCLUSIONS: The outcome for patients with PM RMS has not improved in comparison to previous historical studies, despite the more rigorous application of radiotherapy (94% of patients). Signs of meningeal involvement, PM site, and age at diagnosis remained prognostic risk factors. TRIAL REGISTRATION: EudraCT number 2005-000217-35.
Citation
Head and Neck, 2024,
Source Title
Head and Neck
Publisher
WILEY
ISSN
1043-3074
eISSN
1097-0347